Charitable Act

26 January 2017 By George Hay

Johnson & Johnson has offered $280 per share for the Swiss drugmaker – 70 pct more than it was worth last November. That’s a full price to bolster the U.S. group’s specialist drugs portfolio. Meanwhile, Actelion shareholders get to keep most of the upside from its R&D pipeline.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)